Chi Shang Tai
Direktor/Vorstandsmitglied bei ZICOM GROUP LIMITED
Profil
Chi Shang Tai is the founder of Histoindex Pte Ltd.
He currently holds a position as a Non-Independent Non-Executive Director at Zicom Group Ltd.
Dr. Tai has an undergraduate and doctorate degree from Auckland University.
Aktive Positionen von Chi Shang Tai
| Unternehmen | Position | Beginn |
|---|---|---|
| ZICOM GROUP LIMITED | Direktor/Vorstandsmitglied | 30.11.2020 |
Histoindex Pte Ltd.
 Histoindex Pte Ltd. Medical SpecialtiesHealth Technology Histoindex Pte Ltd. is a medtech/healthcare company based in Singapore, Singapore. The stain-free AI platform is currently involved in multiple FDA clinical trials for nonalcoholic steatohepatitis (NASH) and has benefitted more than 150 research and academic institutes, CROs, and biopharma companies worldwide in drug discovery and development efforts for fibrotic diseases and cancers. Founded in 2010, the Singaporean company specializes in its proprietary integrated stain-free AI digital pathology platform that accurately quantifies histological features and fine measurements critical for the evaluation of therapeutic efficacy in clinical trials. The company was founded by Gideon Ho, Chi-Shang Tai, and Gideon Ho has been the CEO since incorporation. | Gründer | 01.04.2010 |
Ausbildung von Chi Shang Tai
| Auckland University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ZICOM GROUP LIMITED | Producer Manufacturing |
| Private Unternehmen | 1 |
|---|---|
Histoindex Pte Ltd.
Histoindex Pte Ltd. Medical SpecialtiesHealth Technology Histoindex Pte Ltd. is a medtech/healthcare company based in Singapore, Singapore. The stain-free AI platform is currently involved in multiple FDA clinical trials for nonalcoholic steatohepatitis (NASH) and has benefitted more than 150 research and academic institutes, CROs, and biopharma companies worldwide in drug discovery and development efforts for fibrotic diseases and cancers. Founded in 2010, the Singaporean company specializes in its proprietary integrated stain-free AI digital pathology platform that accurately quantifies histological features and fine measurements critical for the evaluation of therapeutic efficacy in clinical trials. The company was founded by Gideon Ho, Chi-Shang Tai, and Gideon Ho has been the CEO since incorporation. | Health Technology |
